David L Blum

This study identifies AETA peptide as a novel contributor to synaptic dysfunction in Alzheimer's disease, particularly in females, through post-mortem analysis and a mouse model.

The paper uses single-domain antibodies to investigate how different tau domains influence RNA-induced tau liquid-liquid phase separation, identifying a proline-rich domain as critical for condensation.

This study identifies and characterizes a novel N-terminally acetylated Tau variant that accumulates in AD models and patients, exacerbates pathology, and is a potential therapeutic target.

This study shows that platelet concentrate-derived extracellular vesicles enhance adult hippocampal neurogenesis in both ex vivo and in vivo models.

This study shows that maternal high-fat diet during lactation accelerates tauopathy in THY-Tau22 mice, with sex-dependent effects where males are more affected earlier than females.

This study shows that platelet-derived biomaterials reduce mitochondrial dysfunction in neuronal injury models by restoring ATP production, reducing ROS, and improving mitochondrial structure and function.

The paper screens patients with parkinsonism for RFC1 gene expansions and finds that Parkinson's disease and multiple system atrophy can be gateways to RFC1-related disorders.

This study shows that inhibiting ENT1 with J4 reduces Tau-mediated neurodegeneration in a mouse model by improving energy homeostasis and mitigating immune responses.

The paper identifies AD risk genes that influence microglia response to amyloid-β but not TAU pathology in mouse models.

The paper shows that early-life caffeine exposure in Tau22 transgenic mice accelerates cognitive deficits linked to Alzheimer's-like pathology.